日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CRISPR activation for SCN2A-related neurodevelopmental disorders

CRISPR激活治疗SCN2A相关神经发育障碍

Tamura, Serena; Nelson, Andrew D; Spratt, Perry W E; Hamada, Elizabeth C; Zhou, Xujia; Kyoung, Henry; Li, Zizheng; Arnould, Coline; Barskyi, Vladyslav; Krupkin, Beniamin; Young, Kiana; Zhao, Jingjing; Holden, Stephanie S; Sahagun, Atehsa; Keeshen, Caroline M; Lu, Congyi; Ben-Shalom, Roy; Taloma, Sunrae E; Schamiloglu, Selin; Li, Ying C; Min, Lia; Jenkins, Paul M; Pan, Jen Q; Paz, Jeanne T; Sanders, Stephan J; Matharu, Navneet; Ahituv, Nadav; Bender, Kevin J

Evaluation of the validity of a perfluorooctane sulfonic acid exposure reconstruction using a measured serum concentration among workers with a wide range of exposure

利用测得的血清浓度对不同暴露水平的工人进行全氟辛烷磺酸暴露重建的有效性评估

Campbell, Jerry L Jr; Linakis, Matthew W; Porter, Anna K; Rosen, Emma M; Logan, Perry W; Kleinschmidt, Sarah E; Andres, Kara L; Chang, Sue; Taiwo, Oyebode A; Olsen, Geary W; Clewell, Harvey J 3rd; Longnecker, Matthew P

Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation

血清鳞状细胞癌抗原监测在宫颈癌根治性放化疗后复发预测中的准确性

Shi, Victoria; Grover, Surbhi; Huang, Yi; Thaker, Premal H; Kuroki, Lindsay M; Powell, Matthew A; Mutch, David G; Contreras, Jessika A; Schwarz, Julie K; Grigsby, Perry W; Markovina, Stephanie

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production

SCCA1/SERPINB3通过STAT依赖性趋化因子产生抑制抗肿瘤免疫并减弱治疗诱导的T细胞反应。

Liyun Chen ,Victoria Shi ,Songyan Wang ,Lulu Sun ,Rebecca Freeman ,Jasmine Yang ,Matthew J Inkman ,Subhajit Ghosh ,Fiona Ruiz ,Kay Jayachandran ,Yi Huang ,Jingqin Luo ,Jin Zhang ,Pippa Cosper ,Clifford J Luke ,Catherine S Spina ,Perry W Grigsby ,Julie K Schwarz ,Stephanie Markovina

Neighborhood Characteristics and Elevated Blood Pressure in Older Adults

社区特征与老年人高血压的关系

Sims, Kendra D; Willis, Mary D; Hystad, Perry W; Batty, G David; Bibbins-Domingo, Kirsten; Smit, Ellen; Odden, Michelle C

Expanding the toolbox of metabolically stable lipid prodrug strategies

扩展代谢稳定的脂质前药策略工具箱

Kiran S Toti, Nicole Pribut, Michael D'Erasmo, Madhuri Dasari, Savita K Sharma, Perry W Bartsch, Samantha L Burton, Hannah B Gold, Anatoliy Bushnev, Cynthia A Derdeyn, Adriaan E Basson, Dennis C Liotta, Eric J Miller

Integrated Primary Care and Health Behavior Support: A Survey of Behavioral Health Providers

整合式初级保健和健康行为支持:行为健康服务提供者调查

Nederveld, Andrea; Wiggins, Kimberly; Dickinson, Linda Miriam; Dickinson, Perry W; Tolle, Lauren Woodward; Holtrop, Jodi Summers

SCCA1/SERPINB3 promotes suppressive immune environment via STAT-dependent chemokine production, blunting the therapy-induced T cell responses

SCCA1/SERPINB3 通过 STAT 依赖性趋化因子产生来促进抑制性免疫环境,从而减弱治疗诱导的 T 细胞反应

Liyun Chen, Victoria Shi, Songyan Wang, Rebecca Freeman, Fiona Ruiz, Kay Jayachandran, Jin Zhang, Pippa Cosper, Lulu Sun, Clifford J Luke, Catherine Spina, Perry W Grigsby, Julie K Schwarz, Stephanie Markovina

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

2019 年冠状病毒病轻度至中度高危患者接受 Bamlanivimab-Etesevimab 和 Casirivimab-Imdevimab 治疗后严重不良事件发生率

O'Horo, John; Challener, Douglas W; Anderson, Ryan J; Arndt, Richard F; Ausman, Sara E; Hall, Scott T; Heyliger, Alexander; Kennedy, Brian D; Sweeten, Perry W; Ganesh, Ravindra; Razonable, Raymund R

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019

遏制 Delta 激增:使用 Bamlanivimab-Etesevimab、Casirivimab-Imdevimab 或 Sotrovimab 治疗轻度至中度 2019 冠状病毒病后的临床结果

Razonable, Raymund R; O'Horo, John C; Challener, Douglas W; Arndt, Lori; Arndt, Richard F; Clune, Caroline G; Culbertson, Tracy L; Hall, Scott T; Heyliger, Alexander; Jackson, Tammy A; Kennedy, Brian D; Larsen, Jennifer; Hanson, Sara N; Sweeten, Perry W; Tulledge-Scheitel, Sidna M; Ganesh, Ravindra